Home › Companies › ACTU

Actuate Therapeutics

ACTU Lead: Phase 2 8 Biotech Distilled articles ↓

Oncology Small Molecule

Most recent annual filing: 2026-01-15

Pipeline (7 active programs)

Elraglusib Injection

elraglusib · 9-ING-41

Small Molecule Target: GSK-3β

Metastatic Pancreatic Ductal Adenocarcinoma Phase 2 intravenous NCT03678883
Ewing Sarcoma Phase 1 intravenous NCT04239092

Elraglusib Oral Tablet

elraglusib · 9-ING-41

Small Molecule Target: GSK-3β

Undisclosed indication Phase 1 oral

elraglusib

Target: GSK-3β

Metastatic Melanoma Phase 1 oral
Non-Small Cell Lung Cancer Phase 1 oral
Colorectal Cancer Phase 1 oral
Pancreatic Ductal Adenocarcinoma Phase 1 oral

Biotech Distilled coverage (8)

2026-05-12 UPDATE: Actuate Therapeutics (ACTU) - The Mersana Guy Just Joined the Board 🔒 Paid
2026-04-27 UPDATE: Actuate Therapeutics (ACTU) - Nature Medicine Blesses the Sledgehammer 🔒 Paid
2026-03-29 UPDATE: Actuate Therapeutics (ACTU) - The "Going Concern" Ghost and the July 2026 Cliff 🔒 Paid
2026-03-15 UPDATE: Actuate Therapeutics (ACTU) - A Great Science Project Doesn't Pay the Bills 🔒 Paid
2026-01-25 Update : Actuate Therapeutics (ACTU) Goes Oral - A Lazarus Patient, A Pill, and An Empty Checkbook 🔒 Paid
2026-01-13 UPDATE : Actuate Therapeutics (ACTU) Post-ASCO: The "Tail" Looks Real, but Is the Market is Blind? 🔒 Paid
2026-01-12 UPDATE: Actuate Therapeutics (ACTU) — Finding Green Shoots in the Graveyard 🔒 Paid
2026-01-07 Actuate Therapeutics (ACTU): Scientific Deep Dive for Elraglusib 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.